Fig. 5

The fusion of non-treated (NT) and IGF-1-, IL-4-, IL-6-, or SDF-1-treated or pre-treated human and pig BM-MSCs (hBM-MSCs and pBM-MSCs) with C2C12 myoblasts. a The percentage of hybrid myotubes in co-culture of treated hBM-MSCs and C12C12 myoblasts in the proliferating medium (PM) for 7 days (n = 3). b The percentage of hybrid myotubes and the fusion index in co-culture of treated hBM-MSCs and C12C12 myoblasts in the differentiating medium (DM) for 7 days (n = 3). c The percentage of hybrid myotubes and fusion index in co-culture of hBM-MSCs and C2C12 myoblasts pre-treated for 3 days in control (without selected factor supplementation) proliferating medium (PM) for 7 days (n = 3). d The percentage of hybrid myotubes and fusion index in co-culture of non-treated (NT) or treated pBM-MSCs and C2C12 myoblasts in the differentiating medium (DM) after 7 days (n = 3). e hBM-MSC localization in myotubes in co-cultures with C2C12 myoblasts after 7 days of IGF-1, IL-4, IL-6, or SDF-1 treatment in PM and DM. Scale bar 50 μm. Blue—cell nuclei, red—skeletal myosin, green—human cell nuclei. *p < 0.05, **p < 0.01, ***p < 0.005